Additional clinical studies demonstrated a strong association between high PD-L1 expression prior to anti-PD-1/PD-L1 therapy with improved ORRs and survival in patients with various cancers including non-small-cell lung cancer, neck squamous cell carcinoma, and melanoma [43,44,45]. This evidence concerns the gene CD274 and non-small cell lung carcinoma.